Deferiprone is an iron chelator used to treat patients with transfusional iron overload caused by thalassemia syndromes. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin.
- Mechanism
- Curator reviewed
Deferiprone is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Deferiprone is more selective for iron in which other metals such as zinc, copper, and aluminum have a lower affinity for deferiprone.
- Primary indication
- Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.Curator reviewed · 2 structured indications
- Formula / weight
- C7H9NO2 · 139.1519 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2011 · European Union, 2016
- Code names
- APO-066 · APO-66 · CP-20 · DN-180-01-AF · L-1
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
TZXKOCQBRNJULO-UHFFFAOYSA-NSMILESCN1C=CC(=O)C(O)=C1CTargets
What you can answer from here — as of September 15, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Deferiprone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account